Cytometric study of intracellular P-gp expression and reversal of drug resistance

Cytometry

Volumn 32, Issue 2, 1998, Pages 86-94

  Labroille, Gilles ^a,b   Belloc, Francis ^a,b   Bilhou Nabera, Chrystéle ^a,b   Bonnefille, Sabine ^a   Bascans, Elisabeth ^a   Boisseau, Michel R ^a,b   Bernard, Philippe ^a,b   Lacombe, Francis ^a,c  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c CNRS Bordeaux Segalen University   (France)

Author keywords

Antisense oligonucleotides; Leukemia cell lines; Multidrug resistance; P glycoprotein; Triple helix generation

Indexed keywords

BREFELDIN A; CELL SURFACE PROTEIN; CYCLOHEXIMIDE; DNA FRAGMENT; GLYCOPROTEIN P; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOFLUORESCENCE TEST; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032101907     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19980601)32:2<86::AID-CYTO3>3.0.CO;2-C     Document Type: Article

References (23)

1. Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT, Dalton WS: Evidence for a cytopfasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res 56:5435-5442, 1996.
2. Alley MC, Uhl CB, Lieber MM: Improved detection of drug cytotoxicity in the soft agar colony formation assay through use of a metabolizable tetrazolium salt. Life Sciences 31:3071-3078, 1982.
3. Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SPC, Deeley RG: Characterization of the Mr 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res 55:102-110, 1995.
4. Bennet MR: The use of antisense oligomtcleotides as therapeutic agents: A review. J Drug Dev Clin Pract 7:225-237, 1995.
5. Bilhou-Nabera C, Viard F, Marit G, Gharbi MJ, Salzes S, Reiffers J, Broustet A, Bernard PH: Complete cytogenetic conversion in chronic myelocytic leukemia patients undergoing interferon alpha therapy: Follow up with reverse polymerase chain reaction. Leukemia 6:595-598, 1992.
6. Fojo AT, Ueda K, Slamon DJ, Poplack DJ, Gottesman MM, Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269, 1987.
7. Gottesman MM, Pastan I: The multidrug transporter, a double-edged sword. J Biol Chem 263, 25:12163-12166, 1988.
8. Gottesman MM, Pastan I: Clinical trials of agents that reverse multidrug-resistance. J Clin Oncol 7:409-411, 1989.
9. Juranka PF, Zastawny RL, Ling V: P-glycoprotein: Multidaig resistance and a superfamily of membrane associated transport proteins. FASEB J 3:2583-2592, 1989.
10. Labroille G, Bonnenlle S, Belloc F: TFX™ -50 reagent increases the uptake of oligonucleotides by leukemic cells. Promega Notes Magazine 56:8-13, 1996.
11. Lippincott-Schwartz J, Yan LC, Bonifacino JS, Klausner RD: Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: Evidence for membrane cycling from the Golgi to ER. Cell 56:801-813, 1989.
12. Mahon FX, Belloc F, Reiffers J: Antisense oligomers in chronic myeloid leukemia. Lancet 341:566, 1993.
13. Ng WF, Sarangi F, Zastawny RL, Veinit-Drebot L, Ling V: Identification of members of the P-Glycoprotein multigene family. Mol and Cell Biol 9,3:1224-1232, 1989.
14. Postel EH, Flint SJ, Kessler DJ, Hogan ME: Evidence that a triplex forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc Natl Acad Sci USA 88:8227-8231, 1991.
15. 1, and 7-chloro-4-nitrobenz-2-oxa-l,3-diazole (NBD) of cellular accumulation and intracellular distribution of anthracyclines in the non-P-glycoprotein-mediated multidrug-resistant cell line CORL23-R. Br J Cancer 70:60-66, 1994.
16. Rojanasakul Y: Antisense oligonucleotide therapeutics: Drug delivery and targeting. Advanced Drug Delivery Review 18:115-131, 1996.
17. Rothenberg M, Ling V: Multidnig resistance: Molecular biology and clinical relevance. J Natl Cancer Inst 81:907-913, 1989.
18. Sanford MS, Mevin S: Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91:3497, 1994.
19. Scaggiante B, Morassutti C, Tolazzi G, Michelutti A, Baccarani M, Quadrifoglio F: Effect of unmodified triple helix-forming oligodeoxyri-bonucleotide targeted to human multidrug-resistance gene mdr1 in MDR cancer cells. FEBS Lett 352:380-384, 1994.
20. Scanlon KJ, Ohta Y, Ishida H, Kijima H, Ohkawa T. Kaminski A, Tsal J, Horng G, Kashani-Sabet M: Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J 9:1288-1296, 1995.
21. Sczakiel G: Antisense strategies in the treatment of hematological malignancies. Stem Cells 13:88-92, 1995.
22. Smetsers T, Van de Locht L, Pennings A. Wessels H, De Witte T, Mensink E: Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death but fail to reduce cellular Bcr-Abl protein levels. Leukemia 9:118, 1995.
23. Thomas TJ, Faaland CA, Gallo MA, Thomas T: Suppression of c-myc oncogene expression by a polyamine-complexed triplex forming oligonucleotide in MCF-7 breast cancer cells. Nucleic Acid Res 23:3594-3599, 1995.